What are the common side effects of Mobotinib?

Mobocertinib (also known as Mobocertinib, English name: Mobocertinib) is an oral targeted drug mainly used to treat patients with EGFR exons n>20Patients with non-small cell lung cancer (NSCLC) with insertional mutations, especially those who have progressed after receiving platinum-based chemotherapy. As a drug that specifically targets this rare EGFR mutation, mobotinib brings hope to some patients who originally lacked effective treatment options. However, like all anti-cancer drugs, while Mobotinib exerts its therapeutic effect, it may also cause certain adverse reactions, and patients should pay attention and manage them during use.

First, one of the most common side effects of mobotinib is gastrointestinal effects. A large amount of clinical research data shows that diarrhea is the most frequent adverse reaction after using Mobotinib. Many patients will experience varying degrees of diarrhea in the early stages of treatment, and some even reach moderate to severe severity, affecting their quality of life. In addition to diarrhea, nausea, vomiting, loss of appetite, and abdominal pain are common gastrointestinal side effects. These symptoms are particularly noticeable in the early stages of treatment, but some patients can gradually adapt to them over time. If the symptoms are severe or last for a long time, you should seek medical treatment in time. If necessary, you can adjust the dosage or use antidiarrheal and antiemetic drugs under the guidance of a doctor.

Secondly, skin-related problems are also one of the common adverse reactions of mobotinib. Some patients will experience skin reactions such as rash, dryness, itching, and erythema during medication, which are closely related to the inhibitory effect of mobotinib on epidermal growth factor receptor (EGFR). These skin symptoms usually occur in the first few weeks after taking the drug and are mostly concentrated on the face, trunk, or extremities. Although most adverse skin reactions are mild to moderate, if severe redness, swelling, blisters, skin peeling, etc. occur, the drug should be discontinued and medical treatment should be sought as soon as possible. In addition, oral ulcers or dryness are complications that may occur in a small number of patients.

Third, renal and electrolyte disturbances have also been observed in some patients. Mobotinib can cause increased serum creatinine, dehydration, hypokalemia, hypomagnesemia and other conditions. This risk may increase especially when the drug is taken for a long time or when other nephrotoxic drugs are combined. Therefore, during treatment, doctors usually arrange regular blood tests to monitor kidney function and electrolyte levels, and replenish fluids or adjust medication strategies if necessary. Patients should also pay attention to drinking more water at home to avoid aggravation of dehydration caused by diarrhea.

Fourth, electrocardiogram abnormalities and QT interval prolongation are one of the adverse reactions that are more important in clinical practice. Mobotinib may cause arrhythmia or QT interval prolongation in some patients. This is a rare but serious side effect. If not monitored in time, it may induce arrhythmia or even sudden death. Therefore, for patients with a history of heart disease or who are taking other drugs that affect the QT interval, an electrocardiogram should be performed before taking the drug and continuously monitored.

In addition, interstitial lung disease (ILD) or pneumonia, although rare, can be serious or even fatal adverse events. If a patient develops persistent cough, difficulty breathing, fever and other symptoms while taking the medication, the medication should be stopped immediately and checked for pulmonary infection or drug-related pneumonia. Early recognition and treatment of such problems is critical to reducing serious complications.

In general, the adverse reactions of mobotinib are similar to other EGFR targeted drugs, focusing on the gastrointestinal tract, skin system, electrolyte imbalance, and cardiopulmonary function. Most side effects are mild to moderate and can be controlled through symptomatic and supportive treatment, appropriate dose reduction, or temporary discontinuation of the drug. However, for the elderly, frail people or patients with multiple comorbidities, special attention needs to be paid to drug safety.

Therefore, patients should strictly follow the doctor's instructions while taking Mobotinib, receive regular examinations, pay attention to their physical changes, and report discomfort symptoms in a timely manner. Correct handling of side effects not only helps improve the quality of life, but also ensures the continuity and effectiveness of treatment. In the future, as more experience is accumulated and treatment options are optimized, the clinical application of mobotinib will become more mature and safer.

References：https://en.wikipedia.org/wiki/Mobocertinib